Evidence map›Paper›PMID 39319579›Full record

ArticleChemMedChem2024

Lasamide Containing Sulfonylpiperazines as Effective Agents for the Management of Glaucoma Associated Symptoms.

Jaydeo T Kilbile, Suryakant B Sapkal, Gioele Renzi, Ilaria D'Agostino, Mohamed Boudjelal, Yasinalli Tamboli, Luigi Cutarella, Mattia Mori, Silvia Sgambellone, Serafina Villano and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jaydeo T KilbileDepartment of Chemistry, School of Basic and Applied Sciences, MGM University, Chhatrapati Sambhajinagar, 431003, MS, India.
Suryakant B SapkalDepartment of Chemistry, School of Basic and Applied Sciences, MGM University, Chhatrapati Sambhajinagar, 431003, MS, India.
Gioele RenziNEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, 50019, Sesto Fiorentino, Florence, Italy.
Ilaria D'AgostinoNEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, 50019, Sesto Fiorentino, Florence, Italy.
Mohamed BoudjelalKing Abdullah International Medical Research Center (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh, 14811, Saudi Arabia.
Yasinalli TamboliKing Abdullah International Medical Research Center (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh, 14811, Saudi Arabia.
Luigi CutarellaDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, via Aldo Moro 2, 53100, Siena, Italy.
Mattia MoriDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, via Aldo Moro 2, 53100, Siena, Italy.
Silvia SgambelloneNEUROFARBA Department, Section of Pharmacology and Toxicology, University of Florence, 50139, Florence, Italy.
Serafina VillanoNEUROFARBA Department, Section of Pharmacology and Toxicology, University of Florence, 50139, Florence, Italy.
Silvia MarriNEUROFARBA Department, Section of Pharmacology and Toxicology, University of Florence, 50139, Florence, Italy.
Laura LucariniNEUROFARBA Department, Section of Pharmacology and Toxicology, University of Florence, 50139, Florence, Italy.
Simone CarradoriDepartment of Pharmacy, University "G. d'Annunzio" Chieti-Pescara, 66100, Chieti, Italy.
Fabrizio CartaNEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, 50019, Sesto Fiorentino, Florence, Italy.
Claudiu T SupuranNEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, 50019, Sesto Fiorentino, Florence, Italy.

Funding

King Abdullah International Medical Research Center (KAIMRC) NRC23R/680/10
6 · The paper itself

Abstract

A series of 2,4-dichloro-5-{[4-(phenylsulfonyl)piperazin-1-yl]carbonyl}benzenesulfonamides were designed and synthesized through amidation of Lasamide 1 with substituted piperazines. The newly obtained compounds demonstrated remarkable inhibition potency and selectivity for the human (h) expressed Carbonic Anhydrase (CA; EC 4.2.1.1) II isoform. Selected compounds 7 and 9 were investigated in an in vivo model of glaucoma and showed relevant performances, with the latter being able to last the effect up to 4 hours. The results herein reported are in sustainment of Lasamide derivatives as a new class of compounds potentially exploitable for the management of uncontrolled intra ocular pressure (IOP).

Indexed as

Carbonic Anhydrase InhibitorsGlaucomaPiperazinesSulfonamidesAnimalsCarbonic Anhydrase IIHumansIntraocular PressureMolecular StructureStructure-Activity RelationshipCarbonic Anhydrase IICarbonic Anhydrase InhibitorsPiperazinesSulfonamidesCarbonic AnhydraseGlaucomaIOPLasamideSulfonylpiperazines

Identifiers

PMID39319579
PMCPMC11648825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.